Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,597 across all filing types
Latest filing 2016-02-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于最近五年未被证券监管部门和交易所采取处罚或监管措施的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Guangdong Taicheng Pharmaceutical Co., Ltd. stating that in the past five years, the company has not been subject to any penalties or regulatory measures by securities regulatory authorities or exchanges. It mentions the company's intention to implement a non-public issuance of A-shares but does not contain any financial data or detailed report content. The document is only 525 characters long and serves as a regulatory compliance disclosure related to the company's regulatory status. It does not fit into categories like Annual Report, Interim Report, or Capital/Financing Update, but rather is a regulatory announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2016-02-28 Chinese
关于本次非公开发行方案涉及关联交易事项的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a non-public share issuance plan involving related party transactions. It details the transaction terms, pricing, board approvals, and regulatory requirements. It is not a full financial report but a disclosure about a capital raising event and related party dealings. The document is about a financing activity and capital structure change, specifically a non-public issuance of shares. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 4676 characters, which is sufficient for a detailed announcement rather than a brief notice or a report publication announcement.
2016-02-28 Chinese
关于2016年非公开发行股票后填补被摊薄即期回报措施的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Guangdong Taicheng Pharmaceutical Co., Ltd. regarding the impact of a 2016 non-public stock issuance on immediate earnings dilution and the measures to address it. It discusses the financial impact assumptions, risk warnings, necessity and rationality of the financing, investment projects, governance, and commitments by directors and controlling shareholders. The document is focused on a capital raising event (non-public stock issuance), its financial effects, and related corporate governance and risk mitigation measures. It does not contain full financial statements or comprehensive financial performance data typical of an Annual Report or Interim Report. Instead, it is an update on financing activities and related disclosures. Therefore, the document best fits the category of Capital/Financing Update (CAP). The document length (over 12,000 characters) and detailed content support it being a substantive announcement rather than a brief notice or regulatory filing. Hence, the classification is CAP with high confidence.
2016-02-28 Chinese
第三届董事会第四次会议决议的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board of directors meeting of Guangdong Taicheng Pharmaceutical Co., Ltd. It includes multiple voting results on matters related to a non-public issuance of A shares, including termination of a previous issuance, approval of new issuance plans, pricing, issuance quantity, lock-up periods, use of proceeds, and authorization for further actions. The document is not a full financial report but a formal announcement of board decisions regarding capital raising activities. It does not contain financial statements or earnings data but focuses on capital/financing updates and related corporate governance decisions. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (5071 characters) and content confirm it is not a brief announcement or a proxy statement but a substantive board resolution announcement on financing matters.
2016-02-28 Chinese
2015年度业绩快报
Earnings Release Classification · 95% confidence The document is titled '2015 年度业绩快报' which translates to '2015 Annual Performance Express Report' or '2015 Annual Earnings Quick Report'. It contains preliminary financial data for the year 2015, including revenue, profit, net income, earnings per share, and asset information. The document explicitly states that the data is preliminary and unaudited, and it is an earnings summary rather than a full annual report. The length is 1758 characters, which is relatively short and consistent with a brief earnings release rather than a comprehensive annual report. There is no indication that this is a full 10-K or Annual Report, nor is it an announcement of a report publication. The document is a financial results announcement for the year, which fits the definition of an Earnings Release (ER). FY 2015
2016-02-24 Chinese
关于购买广州天盈广场商品房的公告
Capital/Financing Update Classification · 95% confidence The document is a company announcement regarding the purchase of commercial property by Guangdong Taicheng Pharmaceutical Co., Ltd. It details the transaction overview, parties involved, payment terms, and strategic purpose. The document is relatively short (1452 characters) and does not contain financial statements, audit information, or detailed financial performance data. It is not a report but an announcement of a specific transaction related to asset acquisition. This fits best under Capital/Financing Update (CAP) as it relates to company financing activities and capital asset purchases. There is no indication that this is a full report, regulatory filing, or other categories such as M&A or share issuance. Therefore, the classification is CAP with high confidence.
2016-02-02 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.